The purpose of this study is to expand on the ongoing post-marketing monitoring of abatacept to include all participants with rheumatoid arthritis (RA) and psoriatic arthritis (PsA) treated with abatacept captured in Danish Database for Biologic Therapies (DANBIO).
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Incidence Rates of Overall Malignancies
Timeframe: Up to 5 years
Incidence Rates of Melanoma
Timeframe: Up to 5 years
Incidence Rates of Non-melanoma Skin Cancer
Timeframe: Up to 5 years
Incidence Rates of Basal Cell Carcinoma
Timeframe: Up to 5 years
Incidence Rates of Squamous Cell Carcinoma
Timeframe: Up to 5 years